Morgan Stanley upgraded Sumitomo Pharma (DNPUF) to Equal Weight from Underweight with a price target of 1,350 yen, up from 550 yen. Orgovyx sales are “on a roll” with U.S. Medicare changes driving growth, says the analyst, who cites strong U.S. sales as the main reason the firm raised its forecasts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNPUF: